What is the role of sodium channel blocking agents in the treatment of complex regional pain syndrome (CRPS)?

Updated: Jun 20, 2018
  • Author: Gaurav Gupta, MD; Chief Editor: Stephen A Berman, MD, PhD, MBA  more...
  • Print

An IV lidocaine infusion has been shown to be effective in uncontrolled trials for reducing spontaneous and evoked pain with both CRPS types I and II. [85, 86, 87] Mexiletine is not active in central pain and shows poor efficacy in painful diabetic neuropathy. The use of oral mexiletine has not been studied, but clinical experience suggests a benefit for some CRPS patients. Contraindications include side effects that are mainly related to cardiac conduction abnormalities, reduced left ventricular function, and coronary heart disease. [1] The topical 5% lidocaine patch has also been reported to produce clinically significant pain relief under the application site in several patients with CRPS in an uncontrolled series. [88]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!